PanamaTimes

Tuesday, Jul 15, 2025

Plenary session approves project regulating the medicinal use of cannabis in Panama in the last debate

Plenary session approves project regulating the medicinal use of cannabis in Panama in the last debate

The initiative creates a regulatory framework that allows the use, monitored and controlled access of cannabis and its derivatives for medical and scientific purposes.

The Plenary of the National Assembly (AN) approved in the third and last debate the bill No. 153 that regulates the medicinal and therapeutic use of cannabis and its derivatives.

The initiative creates a regulatory framework that allows the controlled and controlled use and access of cannabis and its derivatives for therapeutic, medical, veterinary and research purposes in Panama.

According to the document, all products derived from cannabis for medical and scientific purposes that are cultivated, imported, manufactured, exported, commercialized and investigated in Panama will be subject to a system of surveillance and control by the control authorities.

The Ministry of Health, through the National Directorate of Pharmacies and Drugs, will be the competent authority to issue the license for import, export, re-export for the commercialization of cannabis derivatives, as well as the manufacture of cannabis derivatives for medicinal use.

The National Directorate of Pharmacies and Drugs is in charge of establishing the records of patients who use cannabis for medicinal use, which must include information on the disease and the treating physician, as well as the doses and frequency of treatment.

The project indicates that the licenses issued may not be transferred or assigned under any title.

The types of license will be for the importation of cannabis derivatives for commercialization purposes, a manufacturing license, a license for the use of seeds and cultivation of the cannabis plant, and a license for scientific research.

Licensees will be prohibited from promoting or advertising through the media, social networks, flyers or any means of seeds for planting, cannabis plants, cannabis derivatives and products that contain them.

Medicines may only be advertised in publications of a scientific or technical nature, aimed at doctors, scientists and researchers.

Licensees are also prohibited from allowing minors access to seeds for planting, cannabis plants, cannabis derivatives, and products containing it.

During the discussion in the second debate of the project, the concept of guaranteeing that the medicinal and therapeutic use of cannabis is accessible to the consumer was emphasized, with the aim of avoiding speculation and monopoly of this product.

View the law (Spanish)

Newsletter

Related Articles

PanamaTimes
0:00
0:00
Close
Biden’s Doctor Pleads the Fifth to Avoid Self-Incrimination on President’s Medical Fitness
US Imposes New Tariffs on Brazilian Exports Amid Political Tensions
U.S. Enacts Sweeping Tax and Spending Legislation Amid Trade Policy Shifts
AI Raises Alarms Over Long-Term Job Security
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
OpenAI Secures Multimillion-Dollar AI Contracts with Pentagon, India, and Grab
Brazilian Congress Rejects Lula's Proposed Tax Increase on Financial Transactions
Landslide in Bello, Colombia, Results in Multiple Casualties
Papa Johns pizza surge near the Pentagon tipped off social media before Trump's decisive Iran strike
Juncker Criticizes EU Inaction on Trump Tariffs
Minnesota Lawmaker Melissa Hortman and Husband Killed in Targeted Attack; Senator John Hoffman and Wife Injured
Wreck of $17 Billion San José Galleon Identified Off Colombia After 300 Years
Sole Survivor of Air India Crash Recounts Escape
Coinbase CEO Warns Bitcoin Could Supplant US Dollar Amid Mounting National Debt
UK and EU Reach Agreement on Gibraltar's Schengen Integration
Israeli Finance Minister Imposes Banking Penalties on Palestinians
U.S. Inflation Rises to 2.4% in May Amid Trade Tensions
Trump's Policies Prompt Decline in Chinese Student Enrollment in U.S.
Global Oceans Near Record Temperatures as CO₂ Levels Climb
Trump Announces U.S.-China Trade Deal Covering Rare Earths
Smuggled U.S. Fuel Funds Mexican Cartels Amid Crackdown
Protests Erupt in Los Angeles with Symbolic Flag Burning
Trump Administration Issues New Travel Ban Targeting 12 Countries
Man Group Mandates Full-Time Office Return for Quantitative Analysts
JPMorgan Warns Analysts Against Accepting Future-Dated Job Offers
Builder.ai Faces Legal Scrutiny Amid Financial Misreporting Allegations
Japan Grapples with Rice Shortage Amid Soaring Prices
Goldman Sachs Reduces Risk Exposure Amid Market Volatility
HSBC Chairman Mark Tucker to Return to AIA as Non-Executive Chair
Israel Confirms Arming Gaza Clan to Counter Hamas Influence
Judge Blocks Trump's Ban on International Students at Harvard
Trump Proposes Travel Ban on 'Uncontrolled' Countries
Panama Port Owner Balances US-China Pressures
Trump Administration Accused of Obstructing Deportation Cases
Trump’s China Strategy Remains a Geopolitical Puzzle
Eurozone Inflation Falls Below ECB Target to 1.9%
Call for a New Chapter in Globalisation Emerges
Blackstone and Rivals Diverge on Private Equity Strategy
Mayor’s Security Officer Implicated | Shocking New Details Emerge in NYC Kidnapping Case
Bangkok Ranked World's Top City for Remote Work in 2025
Denmark Increases Retirement Age to 70, Setting a European Precedent
Netanyahu Accuses Western Leaders of 'Emboldening Hamas'
Escalating Trade Tensions and Market Reactions
OnlyFans Reportedly in Talks for $8 Billion Sale
JBS Gains Shareholder Approval for U.S. Stock Listing
Booz Allen Hamilton to Cut 2,500 Jobs Amid Federal Spending Reductions
Trump Signs Executive Orders to Accelerate Nuclear Energy Development
Harvard Temporarily Blocks Trump Administration's International Student Ban
Nippon Steel Forms Partnership with U.S. Steel, Headquarters to Remain in Pittsburgh
Trump Expands Tariff Threats to Apple and Samsung Devices
×